Evidence map›Paper›PMID 40434103›Full record

ArticleJournal of virology2025

Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells.

Matthew Esparza, Sara S El Zahed, Umut Karakus, Hanspeter Niederstrasser, Boning Gao, Kimberly Batten, Jerry W Shay, Bruce Posner, Fred R Hirsch, Luc Girard and 4 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthew Esparza *Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Sara S El Zahed *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Umut KarakusDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hanspeter NiederstrasserDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Boning GaoDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kimberly BattenDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jerry W ShayDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Bruce PosnerDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Fred R HirschCenter for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Luc GirardDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Lily Jun-Shen HuangDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
John MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-6551-1827
Beatriz M A FontouraDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-8468-5315

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody AnalysesU54CA260560 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SHYR, YU · 2020 to 2024
$10.0M
JAK2 signaling in erythropoiesisR01HL089966 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI LILY JUNSHEN HUANG · 2007 to 2026
$7.4M
Virulence Factor at the Interface of Viral and Cellular mRNA Nuclear ExportR01AI154635 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Beatriz MA Fontoura · 2020 to 2026
$5.1M
In Cell Analyzer 6000 for UTSW HTS CoreS10OD018005 · OD · UT SOUTHWESTERN MEDICAL CENTER · PI POSNER, BRUCE ARTHUR · 2014 to 2014
$598k
NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS U54 CA260560NHLBI NIH HHS R01 HL089966NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI154635NIAID NIH HHS U19 AI135972NIH HHS S10 OD018005
6 · The paper itself

Abstract

Lung cancers develop from lung epithelial cells after a series of genetic and epigenetic changes, and these cells are major sites of influenza virus infection. Thus, we explored how changes found in patient-derived lung cancer cell lines impacted influenza virus replication and identified two lines with opposite responses to influenza A viral infection. We show that the NCI-H820 lung adenocarcinoma (LUAD) is resistant to influenza A virus and VSV infection, while LUAD line NCI-H322 is highly susceptible to infection by both viruses. H322 cells have a homozygous deletion in a region of chromosome 9 encoding IFNαgenes, IFNβ1, IFNω1, and IFNε genes, leading to downregulation of immune response and high infection rates. In contrast, the resistant H820 cell line has three copies of these same interferon genes and shows increased expression of interferon-regulated genes. We found that the resistance of H820 cells to influenza infection is likely linked to impaired viral entry-due to high basal levels of interferon-induced proteins known to inhibit endocytosis (IFITM1/2/3, NCOA7, and CH25H)-and to increased expression of mRNAs that encode other antiviral factors. In contrast, H322 cells show the absence or low levels of interferon-regulated genes involved in the inhibition of viral entry. These results suggest that the opposite phenotypes on viral entry of H322 and H820 cells may be at least in part associated with impaired or enhanced interferon response, respectively. Since most lung cancer patients have genomic characterization of their tumors, individualized differences in interferon responses may have therapeutic and patient management implications. IMPORTANCE: Lung cancers develop from genetic and epigenetic changes that can dramatically influence patients' susceptibility to viral infection and replication. This study evaluates the responses to influenza virus infection of two patient-derived lung cancer cell lines. Interestingly, the cell lines investigated are of the same cancer type, lung adenocarcinomas, yet one cell line is highly susceptible, while the other cell line is highly resistant to viral infection. This is in part due to contrasting genetic alterations that lead to changes in the interferon response pathways, which differentially impact viral entry. Thus, identifying these risk factors can inform the prognosis of patients infected with influenza virus and guide their personalized treatment plans.

Indexed as

Adenocarcinoma of LungInfluenza A virusInfluenza, HumanInterferonsLung NeoplasmsCell Line, TumorHumansVirus InternalizationVirus ReplicationInterferonsinfluenzainterferonslung cancerviral entry

Identifiers

PMID40434103
PMCPMC12172473

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.